Current precision therapies used in the treatment of cancer are designed to exploit a variety of different biological entities characteristic to individual cancer types, such as activated protein kinases, estrogen receptor, and defective DNA repair enzymes [4,5,6]. This evidence concerns the gene WEE1 and cancer.